
New class of KRAS inhibitors shows promise in shrinking NF1 nerve tumors
A scientist at Cincinnati Children’s who has hunted for decades for ways to shrink the painful and disfiguring nerve tumors caused by neurofibromatosis type 1 (NF1) has made a new breakthrough in the quest.








